ClinicalTrials.gg
WithdrawnNCT06298838Updated Nov 6, 2026

High-resolution Intra-operative PSMA PET-CT in Prostate Cancer

An observational study in Prostate Cancer, sponsored by IRCCS San Raffaele. Withdrawn. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by IRCCS San Raffaele · Observational

How we know

Why this study was withdrawn
Difficulties in patient recruitment
Updated Nov 6, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Prostatic Neoplasms by IRCCS San Raffaele — 7 open to participants now, 9 under way, none of them phase 3. Prostatic Neoplasms · IRCCS San Raffaele.

Enrollment
18th of 18
0 · median 251
Started
2026
with 1 other
Observational
18 of 28
4 open now
Registered
21st of 28
by date

Among the 28 studies in Prostatic Neoplasms by IRCCS San Raffaele, this one is the 18th largest by enrollment of the 18 observational ones that give a count, is one of 2 that started in 2026, is one of 18 observational ones, and was the 21st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 28 studies in Prostatic Neoplasms by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Prostatic Neoplasms by IRCCS San Raffaele, or all of them as a file.
02

Study summary

This is a Single-center, diagnostic open-label prospective, pilot study in a total of 10 patients affected by Prostate cancer (PCa) with a risk of lymph node invasion (LNI) higher than 5% and candidates for a robot-assisted radical prostatectomy (RARP) with an extended pelvic lymph node dissection (ePLND) .

The aim of the trial is to evaluate the feasibility and accuracy and clinical value of a novel high-resolution perioperative PET-CT-scan for intraoperative margin and lymph node invasion assessment, after 18F-PSMA injection, using histopathology as the gold standard.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients affected by Prostate cancer (PCa) with a risk of lymph node invasion (LNI) higher than 5% and candidates for a robot-assisted radical prostatectomy (RARP) with an extended pelvic lymph node dissection (ePLND) according to the European Association of Urology (EAU) guidelines.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male patient, 18 years of age or older.
  2. Patient is confirmed with high risk prostate cancer.
  3. Patient is indicated to undergo radical prostatectomy and ePLND.
  4. Patient is estimated compliant for study participation by the investigator.
  5. Patient has freely given his/her to participate in this study.

Exclusion criteria

Exclusion Criteria:

  1. Patient has general or local for radical prostatectomy.
  2. Patient has active viral or fungal infection.
  3. Patient previously received radiotherapy of the prostate.
  4. Patient participated in other clinical studies with radiation exposure of more than 1 mSv in the past year.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Interventions

  • DeviceAURA10® Specimen PET/CT imager

    The AURA10 PET-CT specimen imager detects and measures the electron density distribution of a specimen and the radiotracer distribution within a specimen. The function of the system is to acquire and visualize PET and CT images of a specimen, based on which a healthcare professional can rapidly verify whether the correct tissue has been resected. It can be used in any condition that requires resection surgery to visualize the resected specimen. The device is automated and semi-quantitative, i.e., qualitative regarding visualization of structure and radiotracer distribution and quantitative regarding tissue density (Hounsfield units) and radiotracer uptake in the specimen (Bq/ml). The type of specimen required is resected tissue from a patient undergoing resection surgery.

06

What researchers measure

Primary outcomes

  1. To investigate the performance characteristics (sensitivity and specificity) of a novel high-resolution perioperative PET-CT-scan for intraoperative margins and lymph node invasion assessment after 18F-PSMA using histopathology as the gold standard

    Time frame: 1 YEAR

Secondary outcomes

  1. Reporting positive lymph nodes detection rate at intraoperative imaging after 18-PSMA injection

    Time frame: 1 YEAR

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 7, 2024
StartEst.
Jun 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Difficulties in patient recruitment
changed Nov 6, 2026
Enrollment
10 (estimated)→0 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Withdrawn
    Why stopped Difficulties in patient recruitment
    Enrollment 10 (estimated)→0 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06298838
Lead sponsor
IRCCS San Raffaele
Responsible party
Giorgio Gandaglia (Assistant Professor, IRCCS San Raffaele) — Principal investigator
First posted
Mar 7, 2024
Start date
Jun 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion